Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.47 |
| ▸ | KIF11 | P52732 | 3/20 | 0.47 |
| ▸ | IDH1 | O75874 | 2/20 | 0.46 |
| ▸ | IDH2 | P48735 | 1/20 | 0.46 |
| ▸ | TRPV3 | Q8NET8 | 7/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381636 | 0.84 | MEN1 (0.60) | NOTUMIDH1IDH2GABRA1GABRG2 | |
| SCHEMBL19072771 | 0.83 | CTSS (0.47) | NOTUMIDH1IDH2TRPV3TGFBR1 | |
| SCHEMBL322547 | 0.83 | ALDH1A1 (0.64) | NOTUMKIF11IDH1IDH2TGFBR1 | |
| SCHEMBL2842049 | 0.83 | NOTUM (0.46) | NOTUMSCN9AIDH1IDH2TGFBR1 | |
| SCHEMBL28345610 | 0.82 | KIF11 (0.65) | SCN9AKIF11TRPV3 | |
| SCHEMBL30395354 | 0.81 | NOTUM (0.58) | NOTUMIDH1IDH2GABRA1GABRG2 | |
| SCHEMBL15624402 | 0.81 | NOTUM (0.58) | NOTUMIDH1IDH2GABRA1GABRG2 | |
| SCHEMBL30755399 | 0.81 | TRPV3 (0.47) | SCN9AKIF11TRPV3 | |
| SCHEMBL8612884 | 0.81 | SCN9A (0.47) | SCN9AKIF11TRPV3 | |
| SCHEMBL1800349 | 0.79 | ASIC3 (0.60) | SCN9AKIF11TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220482-B2 | Aminopyridinemethanol compounds and their use | UNIVERSITE AMIENS PICARDIE JULES VERNE (FR) | 2022-01-11 | — | — | US | disclosed |
| EP-3704093-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | Université Amiens Picardie Jules Verne (FR) | 2020-09-09 | — | — | EP | disclosed |
| US-20200255379-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | UNIV AMIENS PICARDIE JULES VERNE (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220482-B2 | Aminopyridinemethanol compounds and their use | QDPR, PNMT, CYP3A43 | NOTUM 1521/4885SCN9A 1397/4885KIF11 3487/4885 |
| US-20200255379-A1 | NOVEL AMINOPYRIDINEMETHANOL COMPOUNDS AND THEIR USE | QDPR, PNMT, CYP3A43 | NOTUM 1973/4885SCN9A 1141/4885KIF11 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.